The director of Summit Financial Group, Inc. (SMMF), Gary Hinkle Made a Purchase of 3,628 Shares; CONCERT PHARMACEUTICALS (CNCE)’s Sentiment Is 1.18

February 15, 2018 - By Martha Paddon

The director of Summit Financial Group Inc, Gary Hinkle, has just purchased – 3,628 shares of the corporation he’s leading – coming to an aggregate investment of $84,376 U.S. Dollars (this based on average share price of $23.3). Presently, Gary Hinkle owns 454,628 shares which make up roughly 3.68% of Summit Financial Group Inc’s total market capitalization.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $489.61 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. It has a 5.53 P/E ratio. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

Among 2 analysts covering Summit Financial Group (NASDAQ:SMMF), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Summit Financial Group has $26.0 highest and $22 lowest target. $24’s average target is 1.61% above currents $23.62 stock price. Summit Financial Group had 2 analyst reports since October 12, 2016 according to SRatingsIntel. The stock has “Hold” rating by Sandler O’Neill on Monday, September 25.

The stock increased 0.51% or $0.12 during the last trading session, reaching $23.62. About 38 shares traded. Summit Financial Group, Inc. (NASDAQ:SMMF) has risen 14.13% since February 15, 2017 and is uptrending. It has underperformed by 2.57% the S&P500.

Investors sentiment decreased to 2.7 in Q3 2017. Its down 0.30, from 3 in 2017Q2. It fall, as 5 investors sold Summit Financial Group, Inc. shares while 5 reduced holdings. 9 funds opened positions while 18 raised stakes. 2.49 million shares or 11.88% more from 2.22 million shares in 2017Q2 were reported. Rhumbline Advisers owns 11,714 shares. Chicago Equity Partners Llc has 0.01% invested in Summit Financial Group, Inc. (NASDAQ:SMMF). Cornerstone Ltd Llc has 600 shares. Fifth Third Bankshares holds 0.01% in Summit Financial Group, Inc. (NASDAQ:SMMF) or 43,731 shares. Lsv Asset Mngmt invested in 18,900 shares or 0% of the stock. Nationwide Fund Advisors owns 5,987 shares or 0% of their US portfolio. Maltese Capital Mngmt Llc stated it has 0.06% of its portfolio in Summit Financial Group, Inc. (NASDAQ:SMMF). Bancorporation Of America De owns 4,649 shares. California State Teachers Retirement Systems invested 0% of its portfolio in Summit Financial Group, Inc. (NASDAQ:SMMF). Deutsche Natl Bank Ag reported 53,153 shares. Philadelphia Tru Co holds 19,455 shares. Manufacturers Life Insurance Communication The accumulated 8,752 shares. Tower Research Cap Limited Liability Corp (Trc) holds 0% of its portfolio in Summit Financial Group, Inc. (NASDAQ:SMMF) for 984 shares. Moreover, State Street Corporation has 0% invested in Summit Financial Group, Inc. (NASDAQ:SMMF) for 145,595 shares. Pacific Ridge Capital Prtnrs Lc reported 0.18% in Summit Financial Group, Inc. (NASDAQ:SMMF).

Since September 20, 2017, it had 0 buys, and 8 insider sales for $326,298 activity. Cook Julie R also sold $32,751 worth of Summit Financial Group, Inc. (NASDAQ:SMMF) on Wednesday, December 13. The insider BENSENHAVER DEWEY F sold $24,937. 3,125 shares were sold by MCDANIEL DUKE A, worth $76,000. 3 shares were sold by FRYE PATRICK, worth $82. 1,900 shares were sold by MADDY H CHARLES III, worth $51,826 on Friday, December 15.

Summit Financial Group, Inc. operates as a financial holding firm for Summit Community Bank, Inc. that provides community banking and other financial services to individuals and businesses primarily in the Eastern Panhandle and South Central regions of West Virginia and the Shenandoah Valley, and Northern regions of Virginia. The company has market cap of $291.91 million. The firm operates through two divisions, Community Banking, and Insurance & Financial Services. It has a 23.62 P/E ratio. The Company’s community banking services include demand, savings, and time deposits; commercial, commercial real estate, construction and development, residential real estate, and consumer loans; mortgage warehouse lines of credit; letters of credit; and cash management services.

Analysts await Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report earnings on March, 5. They expect $-0.18 earnings per share, up 66.67% or $0.36 from last year’s $-0.54 per share. After $-0.70 actual earnings per share reported by Concert Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -74.29% EPS growth.

The stock increased 0.80% or $0.17 during the last trading session, reaching $21.5. About 19,192 shares traded. Concert Pharmaceuticals, Inc. (CNCE) has risen 18.70% since February 15, 2017 and is uptrending. It has outperformed by 2.00% the S&P500.